Essential Premium

Hedge Funds Capture Big Early Gains in Select Biotech IPOs — With One Notable Exception

Major funds, including Suvretta, RA Capital, and Viking, took sizable stakes ahead of these offerings, positioning themselves to benefit from the sector’s strongest debuts.

CalPERS’ Stephen Gilmore on TPA: ‘This Will Make Management More Accountable’

“The big thing is really around the mentality,” the pension’s CIO says, adding the total approach is “a consistent way of looking at all the investments.”

Sponsored

Asia’s Growing Economic Power Shapes Global Derivatives Market

Tiger Cubs Cash In as Stripe’s Valuation Takes Off

A major secondary sale delivers fresh gains to early hedge fund backers.

Related Content

Biopharma IPO Interest Peaks Following Strong Reception

Steve Taub

Some Hedge Funds Are Behaving More Like Equities. Why Investors Should Care.

Julie Segal

J.P. Morgan’s Michael Cembalest Finds ‘Warning Signs’ in Hedge Funds

Michelle Celarier

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram